Teaming up with NIH, ViiV buys into the next big thing in HIV: antibodies
Weeks after taking over from John Pottage, Kim Smith — ViiV Healthcare’s newly minted head of R&D — has found a new HIV treatment approach to champion and do some heavy lifting around.
The GSK subsidiary has licensed a “broadly neutralizing antibody” from the NIH that promises to recognize and block the entry of multiple HIV strains into healthy CD4+ T cells. By binding to a specific site known as gp120 on the surface of the virus, N6LS is engineered to keep them out and annul any chance of replication inside cells — which can work as either prophylaxis or therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.